Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16134044 | 0.85 | TSHR (0.49) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL23729313 | 0.82 | HPGD (0.46) | TSHRSMN1; SMN2FAAHALDH1A1HPGD | |
| SCHEMBL26708616 | 0.82 | TSHR (0.44) | TSHRSMN1; SMN2MEN1KMT2AFAAH | |
| SCHEMBL23730071 | 0.82 | SMN1; SMN2 (0.53) | TSHRSMN1; SMN2MEN1KMT2AFAAH | |
| SCHEMBL23320108 | 0.81 | TSHR (0.47) | TSHRSMN1; SMN2HPGDADRB2ADRB1 | |
| SCHEMBL19363752 | 0.81 | TSHR (0.47) | TSHRSMN1; SMN2MEN1KMT2AFAAH | |
| SCHEMBL26708162 | 0.81 | TSHR (0.42) | TSHRSMN1; SMN2MEN1KMT2AFAAH | |
| SCHEMBL26708617 | 0.81 | TSHR (0.42) | TSHRSMN1; SMN2MEN1KMT2AFAAH | |
| SCHEMBL26700763 | 0.81 | TSHR (0.42) | TSHRSMN1; SMN2MEN1KMT2AFAAH | |
| SCHEMBL24486573 | 0.80 | TSHR (0.46) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | TSHR 1324/4885SMN1; SMN2 155/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.